Article **Combined BRCA2 and MAGEC3 expression predict outcome in Advanced Ovarian Cancers**

Emmanuel B. Omole¹, Iqbal Aijaz¹, James Ellegate Jr¹, Emily Isenhart^{1,2}, Mohamed M. Desouki³, Michalis Mastri¹, Kristen Humphrey¹, Emily M. Dougherty¹, Spencer R. Rosario², Kent L. Nastiuk^{1,4}, Joyce E. Ohm^{1*} and Kevin H. Eng^{1,2}

- ¹ Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
- Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
- Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

⁴ Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

Correspondence: joyce.ohm@roswellpark.org

Simple Summary: Early detection of ovarian cancer is a significant clinical challenge, with most 14 women presenting with advanced stages of disease at initial diagnosis. The aim of this study was to 15 evaluate the role of MAGEC3 and BRCA2 in epithelial ovarian cancer progression. We evaluated 16 the effect of MAGEC3 and BRCA2 on the other's expression. We tested this in humans using im-17 munohistochemical staining of human tumor samples obtained from patients with epithelial ovar-18 ian cancer (n = 357). We found a weak inverse correlation between MAGEC3 and BRCA2 expression 19 in epithelial ovarian cancers. Further, our data suggests that the combined expression of MAGEC3 20 and BRCA2 may be a better predictor of outcomes in patients than the individual markers alone. 21

Abstract: Like BRCA2, MAGEC3 is an ovarian cancer predisposition gene that has been shown to 22 have prognostic significance in ovarian cancer patients. Despite the clinical significance of each in-23 dividual gene, no studies have been done to assess the clinical significance of their combined ex-24 pression. We therefore sought to determine the relationship between MAGEC3 and BRCA2 expres-25 sion in ovarian cancer and their association with patient characteristics and outcomes. Immuno-26 histochemical staining was quantitated on tumor microarrays of human tumor samples obtained 27 from 357 patients with epithelial ovarian cancer to ascertain BRCA2 expression levels. In conjunc-28 tion with our previously published MAGEC3 expression data, we observed a weak inverse correla-29 tion of MAGEC3 with BRCA2 expression (r=-0.15; p<0.05) in cases with full-length BRCA2. Patients 30 with optimal cytoreduction, loss of MAGEC3, and detectable BRCA2 expression had better overall 31 (median OS: 127.9 vs 65.3 months, p=0.035) and progression-free (median PFS: 85.3 vs 18.8 months, 32 p=0.002) survival compared to patients that were BRCA2 expressors with MAGEC3 normal levels. 33 Our results suggest that combined expression of MAGEC3 and BRCA2 serves as a better predictor 34 of prognosis than each marker alone. 35

Keywords: ovarian cancer; immunohistochemistry; MAGEC3; BRCA2

36 37

38

1

2

3

4

5

6

7

8

9 10

11

12

13

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.17.22278635; this version posted August 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

1. Introduction

Ovarian cancer is a heterogenous disease and it remains the leading cause of mortal-40 ity from gynecologic malignancies, with more than 19,000 new cases and 12,810 deaths 41 expected in the United States in 2022 [1]. Epithelial ovarian cancer (EOC), which accounts 42 for over 90% of all ovarian cancers, is comprised of five distinct subtypes, amongst which 43 high-grade serous ovarian carcinoma (HGSOC) is the most commonly diagnosed [2]. 44 HGSOC is also the most lethal subtype, accounting for about 70% of all epithelial ovarian 45 cancer cases [3, 4] and 70%–80% of all ovarian cancer deaths [5] due to it being diagnosed 46 at an advanced stage [6]. 47

39

Since most women present with advanced stages of disease at initial diagnosis [4, 7, 48 8], early detection of ovarian cancer remains an increasingly important clinical challenge 49 [2, 8, 9]. There is a compelling argument for novel ovarian cancer screening methodolo-50 gies, given that the current strategy results in early detection of ovarian cancer in only 51 ~20% of patients [10]. Advances in ovarian cancer diagnosis include the use of genetic 52 testing to identify mutated genes associated with epithelial ovarian cancer in patients with 53 a known family history of breast and ovarian cancer, such as TP53, PIK3CA, KRAS, and 54 BRCA1/2 [2, 8]. 55

BRCA1/2 genes encode proteins involved in the repair of DNA double-strand breaks 56 via the homologous recombination pathway [11-14]. Germline and somatic mutations, as 57 well as promoter methylation, are the common causes of BRCA1/2 dysfunction [15, 16] 58 which impairs DNA repair leading to increased risk of tumorigenesis [17]. BRCA2 muta-59 tions specifically are associated with a 15-30% lifetime risk of ovarian cancer [18]. Most of 60 the deleterious mutations that have been identified in ovarian cancer families are 61 frameshift (insertions or deletions) mutations or nonsense mutation which result in prem-62 ature termination of the protein-coding sequences [19-22]. Resultant BRCA2 mutant pro-63 teins retain their N-terminal transactivation domain which is enables its recombinational 64 repair and checkpoint roles [23-25] but the C-terminal, which harbors the nuclear locali-65 zation signals (NLS), is lost [25]. The inability to translocate into the nucleus explains why 66 these mutants are nonfunctional and unable to facilitate the DNA repair process in most 67 cases [20, 25, 26]. 68

BRCA1/2 mutations serve as a marker of vulnerability to PARP inhibitors (olaparib, 69 rucaparib, and niraparib). These have become viable treatment options for patients with 70 advanced epithelial ovarian cancer due to enhanced clinical effectiveness and tolerable 71 toxicity [27-31]. While women with BRCA1/2 mutations retain the best response to PARP 72 inhibitors [32], tumors with genomic instability still show clinically significant response 73 to therapy [33], prompting researchers to consider whether other markers like ATM, 74 FANC A/F, CHK2, RAD51B/C, and CDK12 could be used as de facto surrogate markers 75 of deficient homologous repair [34, 35] to expand the pool of women who could benefit 76 from PARP inhibitor therapy. 77

One such potential marker is MAGEC3. MAGEC3 is a member of the "Type II" mel-78 anoma antigen gene (MAGE) family by DNA sequence homology and has low but ubiq-79 uitous protein expression in most tissues with high expression in testes and tonsil [36]. In 80 the context of cancer, members of the family have shown varying functions in DNA repair 81 and cell cycle regulation, [37, 38] as well as potential application as markers of stemness 82 in cancer cells [39]. Biochemically, MAGE proteins bind specifically to E3 RING ubiquitin 83 ligases through their MAGE homology domains (MHDs) and regulate protein ubiquiti-84 nation by enhancing E3 ligase activity [37, 38, 40, 41]. Previously, we described a linkage 85 between early-onset ovarian cancers [42] and MAGEC3 [43, 44] and more recently found 86 that MAGEC3 is a potential prognostic biomarker in ovarian cancer, as loss levels were 87 associated with a favorable progression-free survival (PFS) in ovarian cancer patients [36]. 88

The relationship between both BRCA2 and MAGEC3 protein expression and their 89 clinical significance in ovarian carcinoma is unknown. Immunohistochemistry (IHC) is a 90 low-cost and easily accessible technique that allows for the query of both N- and C-terminal domains of the BRCA2 protein, including protein truncation of the C-terminal of the 92 medRxiv preprint doi: https://doi.org/10.1101/2022.08.17.22278635; this version posted August 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license

BRCA2 protein which severely diminishes protein function [45]. Similarly, IHC has also 93 been used to detect expression of the MAGEC3 protein [36, 46]. Herein, we describe the 94 relationship between MAGEC3 and BRCA2 in patient samples using IHC and tested the 95 hypothesis that their co-expression is correlated with clinical outcome. 96

Two cohorts of patients were used: (1) Patients with advanced high-grade serous

ovarian carcinoma treated at Roswell Park Cancer Institute (RPCI) who had previously

had BRCA2 genetic testing. This cohort was used for the pilot experiment and classified

into three categories based on the results of the genetic testing: BRCA2-Wildtype, BRCA2-

Mutant, and BRCA2-Loss. (2) Patients with a primary diagnosis of ovarian cancer treated

at RPCI by maximal debulking surgery and first-line platinum-based chemotherapy be-

tween 2000 and 2012 were obtained from a curated database under an institutional review

board-approved protocol. Tumor blocks from these cohorts were taken during primary

samples processed as whole tissue sections for the pilot experiment and n = 357 ovarian

cancer patients from cohort 2 with unsequenced tumor samples for the tissue microarray

analysis. The detailed handling protocol for the tissue specimens has been previously de-

In total, there were n = 3 ovarian cancer patients from cohort 1 with sequenced tumor

debulking surgery and prior to the initiation of systemic therapy.

97

98

99

100

101 102 103

104

105

106

107

108

109

110

- 111 112 113
- 114

119

120 121

122

scribed [47]. 115 2.2. Whole Tissue Sections 116 The whole tissue sections derived from formalin-fixed and paraffin-embedded tu-117 118

mor tissues obtained from three sets of sequenced ovarian tumor cases in cohort 1 to qualify antibody reactivity. IHC H-scores were generated using n=30 photographs of randomly selected fields on each slide.

2.3. Tissue Microarray (TMA) Construction

The tissue microarrays (TMA) were constructed using formalin-fixed and paraffin-123 embedded tumor tissues punched from each donor block from cohort 2. Triplicate TMAs 124 (containing three representative cores from each tumor) were prepared and stained to as-125 sess tumor heterogeneity. These TMAs included all epithelial ovarian cancer subtypes, 126 non-tumor control tissues, and reference cores for normalization across different blocks. 127

2.4. Antibody Validation

2. Materials and Methods

2.1. Ovarian Cancer Patients

The Human Protein Atlas [48] (HPA052067) was used to vet the BRCA2 antibodies, in accordance with the International Working Group for Antibody Validation [49] and 131 were evaluated and authorized for IHC and supported for antigen specificity. The BRCA2 antibodies are directed against the BRCA2 C-terminal amino acids (2587-2601 amino acids, Abcam ab53887, Cambridge, MA, USA) and BRCA2 N-terminal amino acids (100-150 amino acids, Proteintech 19791-1-AP, Rosemont, IL, USA).

The MAGEC3 antibody has been previously described [36].

2.5. Immnuhistochemistry

Formalin-fixed paraffin sections were cut at a thickness of 4µm, placed on glass slides 139 and heated at 60°C for 1hour. The TMA sections were then deparaffinized with xylene 140 and ethanol and rinsed in water. For antigen retrieval, slides were pretreated in an antigen 141 retrieval high pH solution (catalog #GV804, Dako, Santa Clara, CA, USA) for 20 min and 142 allowed to cool for 20 min at room temperature. The slides were incubated with a solution 143

129 130

- 132 133
- 134 135
- 136 137
- 138

medRxiv preprint doi: https://doi.org/10.1101/2022.08.17.22278635; this version posted August 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

of 3% H2O2 for 10 minutes. "BRCA2 N-terminal" antibody (catalog #19791-1-AP, Pro-144 teintech, Rosemont, IL, USA) was added to one set of slides at 1:500 dilution while 145 "BRCA2 C-terminal" antibody (catalog# ab53887, Abcam, Cambridge, MA, USA) was 146added to the other set of slides at 1:500 dilution and incubated for 60 minutes at room 147 temperature. This was followed by incubation with biotinylated goat anti-rabbit second-148 ary antibody (catalog # 14708, Cell Signaling Technology, Boston, MA, USA), 1:1000 dilu-149 tion for 15 minutes at room temperature. ABC reagent (catalog #PK 6100, Vector Labs, 150 Burlingame, CA) was used for signal enhancement and applied for 30 minutes. Slides 151 were incubated for 5 minutes with 3,3'-diaminobenzidine (DAB) substrate (catalog 152 #K3467, Dako, Carpinteria, CA) and then counterstained for 20 seconds with DAKO He-153 matoxylin (catalog #CS700, Dako, Carpinteria, CA). Slides were dehydrated in several 154 baths of graded alcohols and xylenes prior to being cover slipped. 155

TMAs were previously stained for MAGEC3 as described [36].

2.6. Digital Image Analysis

Digital images of both IHC-stained whole tissue sections and IHC-stained TMA 158 slides were captured using a whole slide scanner at 10X magnification (Leica ScanScope, 159 Aperio Technologies, UK), and the digital images were stored in SVS format (Aperio). The 160 digital images were retrieved using a file management web interface (eSlide Manager, 161 Aperio) and reviewed with the server software (ImageScope, Aperio, version 12.3.3.5048). 162 Digital images of representative whole tissue section fields and TMA cores were extracted 163 through the server software (ImageScope, Aperio, version 12.3.3.5048) at 10× magnifica-164 tion and quantified into H-scores using an automated IHC profiler built in a digital image 165 analysis software (ImageJ version 1.52a, National Institute of Health, USA) [50]. 166

2.7. Statistical Methods

After the IHC scoring was complete, the optimal cutpoint of the IHC staining score 168 for BRCA2 expression was determined using H-scores obtained for the C-terminal of the 169 sequenced ovarian tumor cases with the aid of the R package, cutpointsr [179]. We strati-170 fied the BRCA2 C-terminal H-scores into two different groups (BRCA2 expressors and 171 BRCA2 non-expressors). 172

All statistical analyses were performed using the R 3.1.2 statistical computing lan-173 guage. Associations between BRCA2/MAGEC3 expression and categorical variables were 174 tested by chi-square tests and continuous variables were tested by one way ANOVA tests. Survival probabilities were calculated by Kaplan-Meier analysis using log-rank testing. A 176 nominal significance threshold of 0.05 was used unless otherwise specified. The multivar-177 iate analysis included stage, categorized as early (I, II, IIIA, or IIIB) or late (IIIC or IV), 178 grade (1 vs. 2/3), debulking status (optimal vs. suboptimal), and platinum-sensitive versus 179 refractory disease. 180

3. Results

3.1. Validation of IHC Measurements of BRCA2 Protein Expression in Cancer Tissue

We first tested whether IHC BRCA2 protein expression confirmed the predicted ex-185 pression by molecularly characterized and sequenced ovarian tumor samples. The 186 adopted two-antibody IHC strategy, which utilizes antibodies specific towards the N-ter-187 minus and C-terminus, allows for discrimination between the presence of normal protein, 188 protein truncation, and loss of protein expression in the tumor samples (Figure 1A). These 189 antibodies were applied to three cases confirmed to have BRCA2 wild type (WT), BRCA2 190 truncating mutation in exon 11 (Mutant), and total loss of BRCA2 (Loss) through sequenc-191 ing. Visual analysis of IHC staining shows that, as expected, wildtype samples have ade-192 quate staining observed with both the N-terminal and C-terminal antibodies, mutant 193

157

156

167

175

181

182 183

samples have staining only at the N-terminal and not the C-terminal, and BRCA2 loss has 194 poor staining intensity seen with for both antibodies (**Figure 1B**). 195



Figure 1. Schematic showing immunohistochemical staining of BRCA2 protein using two-antibody strategy. (A) A full-length gene model, a full-length wild-type protein model bound by both the N-terminal and C-terminal antibodies, and a truncated protein bound by only the N-terminal antibody (loss protein model not shown as it is not expressed and therefore cannot be bound by either antibody). (B) Representative images of sequenced ovarian cases with known genomic status. Wild-type (WT) expression pattern with staining of strong intensity with N-terminal antibody (top left) and moderate intensity with C-terminal antibody (bottom left) in some of the tumor cell nuclei; aberrant expression with moderate staining intensity with N-terminal antibody (top middle) and poor staining intensity with C-terminal antibody (bottom middle) in the verified case with truncating mutation (Mutant); poor staining intensity of both N-terminal (top right) and C-terminal (bottom right) antibodies in the verified case with BRCA2 loss (Loss).

To further validate this strategy, the staining intensity and percentage of positive tu-209 mor cells was quantified using an automated IHC H-scoring algorithm built in ImageJ. The resulting H-scores show that N-terminal expression levels are significantly different 211 between BRCA2 wild type, BRCA2 mutant, and BRCA2 loss in sequenced cases (WT vs Mutant: t-test, p<0.001; WT vs Loss: p<0.001; Mutant vs Loss: p<0.001) (Figure S1). However, given that a truncating mutation renders the protein non-functional, samples that 214 demonstrate lack of C-terminal staining should functionally mimic BRCA2 loss. The difference in C-terminal expression levels when BRCA2 wildtype was compared to BRCA2 216 mutant and BRCA2 loss cases was observed to be statistically significant (WT vs Mutant: 217 t-test, p<0.001; WT vs Loss: p<0.001), while the difference in C-terminal expression levels 218 for the BRCA2 mutant and BRCA2 loss cases was not statistically significant (Mutant vs 219 Loss: t-test, p=0.9) (Figure 2A). Given its ability to differentiate wild-type cases from the 220 functionally impaired mutant and loss cases, C-terminal scoring was used for further anal-221 yses. C-terminal scores for the BRCA2 mutant and BRCA2 loss cases were combined and 222 termed "BRCA2 non-expressors" while the BRCA2 wild-type cases were termed "BRCA2 223 expressors." When the same IHC strategy was applied to 357 unsequenced patient sam-224 ples with unknown BRCA2 status, we used the C-terminal expression levels of the BRCA2 225

expressors and non-expressors to determine an optimal cutoff point for stratifying the 226 unsequenced cases. The optimal cutoff point utilized to stratify the larger unsequenced 227 cohort of patients into "BRCA2 expressors" and "BRCA2 non-expressors" was a H-score of 49.5 (Figure 2B).



Figure 2. BRCA2 protein expression in the sequenced ovarian tumor cases and unsequenced TMAs. (A) C-terminal expression of the BRCA2 wildtype (WT) is statistically different compared to BRCA2 mutant (Mutant) and BRCA2 loss (Loss) in the sequenced ovarian tumor cases, but there is no statistical difference between the Mutant and Loss cases. This was plotted alongside the distribution of unsequenced TMA H-scores. (B) For the sequenced ovarian tumor cases, BRCA2 C-terminal expression of the WT was categorized as BRCA2 expressors (Exp) while those of the Mutant and 237 Loss were grouped as BRCA2 non-expressors (No Exp). An optimal cutoff point of 49.5 was deter-238 mined based on the C-terminal expression levels of the sequenced ovarian tumor cases and was used to stratify the unsequenced ovarian cancer TMA (OVCa TMA) H-scores into Exp and No Exp.

MAGEC3 protein expression quantitation by IHC for patients in this cohort was previously reported in a recent publication from our lab [36]. Expression levels were dichot-243 omized at the median into either "MAGEC3 Normal" or "MAGEC3 Loss" based on the 244 findings that higher levels of MAGEC3 were not significantly different from expression 245 in normal ovary tissue (t-test, p = 0.368), while lower levels of MAGEC3 were significantly 246 lower (t.test, p < 0.001). Given our interest in the combined effect of MAGEC3 and BRCA2 247 expression levels on patient prognosis, we used MAGEC3 expression data from the prior 248 publication as well as the BRCA2 levels ascertained in this study for subsequent analyses. 249

3.2. Clinical Characteristics of Ovarian Cancer Microarray Patient Population

A total of 357 tumor tissues from patients with ovarian and primary peritoneal cancer 252 were analyzed using IHC. From the demographic information of de-identified patients in 253 this study (**Table 1**), the mean age of diagnosis was 63 years (range 21-93 years) and 52.1% 254 of patients were diagnosed after 2006. Most of the patients were white (334; 94.9%), non-255 Hispanic (350; 99.4%), and presented with advanced/late-stage disease (81.5%), poorly dif-256 ferentiated tumors (73.5%) and serous histology (79.6%). Platinum-sensitive disease was 257 demonstrated in 156 of the 357 patients (55.5%) with 125 patients classified as platinum 258 resistant or treatment refractory (42.5%). For survival data, the patients were followed for 259 an average of 65.2 months (maximum 274.2 months). 260

Using the optimal cutoff point calculated above, 299/257 (83.8%) of the patients were 261 classified as BRCA2 expressors while 58/357 (16.2%) were BRCA2 non-expressors. Using 262 the previously reported stratification of MAGEC3, 173/357 (48.5%) of patients in this co-263 hort are MAGEC3 loss while 184/357 (51.5%) are MAGEC3 normal. When considering the 264 combination of BRCA2 and MAGEC3 levels, 34 (9.5%) were BRCA2 non-expressors and 265 showed MAGEC3 loss levels, 139 (40%) were BRCA2 expressors with MAGEC3 loss lev-266 els, 24 (6.7%) were BRCA2 non-expressors with MAGEC3 normal levels, and 160 (44.8%) 267 were BRCA2 expressors with MAGEC3 normal levels. Through extensive statistical 268

231



250

> analysis, BRCA2 expression and normal MAGEC3 levels were associated with cases ascertained after 2006 (Chi-sq test, p<0.001), ovary as primary site of origin (Chi-sq test, p<0.001), poorly/undifferentiated tumors (Chi-sq test, p=0.03) and serous histology (Chisq test, p<0.001). 272

		MAG	Eloss	MAGEnormal			
Characteristic	All Ovary Patients	BRCA2 ^{exp(-)}	BRCA2 ^{exp(+)}	BRCA2 ^{exp(-)}	BRCA2 ^{exp(+)}	<i>p</i> -Value	
-	<i>n</i> = 357	<i>n</i> = 34	<i>n</i> = 139	<i>n</i> = 24	<i>n</i> = 160		
Age of Diagnosis [years]							
Mean (Range)	63 (21-93)	61 (21-85)	63 (31-93)	69 (47-89)	63 (21-89)		
Missing	0	0	0	0	0	0.1†	
Year of Diagnosis [n (%)]							
Before 2006	177 (52.1)	14 (43.8)	104 (81.9)	5 (21.7)	54 (34.2)	<0.001+	
After 2006	163 (47.9)	18 (56.3)	23 (18.1)	18 (78.3)	104 (65.8)	<0.001	
Missing	17	2	12	1	2		
Race [n (%)]							
White	334 (94.9)	31 (94)	130 (96.3)	24 (100)	149 (93.1)		
Black or African American	8 (2.3)	1 (3)	0 (0)	0 (0)	7 (4.4)	0.28	
Other	10 (2.8)	1 (3)	5 (3.7)	0 (0)	4 (2.5)	0.29	
Missing	5	1	4	0	0		
Hispanic [n (%)]							
No	350 (99.4)	34 (100)	133 (99.3)	24 (100)	159 (99.4)		
Yes	2 (0.6)	0 (0)	1 (0.7)	0 (0)	1 (0.6)	0.9§	
Missing	5	0	5	0	0	U	
Primary [n (%)]							
Ovary	310 (88.1)	27 (81.8)	131 (94.9)	16 (66.7)	136 (86.6)		
Primary Peritoneal	42 (11.9)	6 (18.2)	7 (5.1)	8 (33.3)	21 (13.4)	<0.001‡	
Missing	5	1	1	0	3	·	
FIGO Stage [n (%)]							
I/II/IIIA/B	65 (18.5)	8 (24.2)	28 (20.6)	4 (17.4)	25 (15.7)	0.64	
IIIC/IV	286 (81.5)	25 (75.8)	108 (79.4)	19 (82.6)	134 (84.3)	0.6Ţ	
Missing	6	1	3	1	1		
Grade [n (%)]							
Well/Moderately differentiated	93 (26.5)	5 (14.7)	44 (32.6)	2 (8.3)	42 (26.6)	0.024	
Poorly/Undifferentiated	258 (73.5)	29 (85.3)	91 (67.4)	22 (91.7)	116 (73.4)	0.03‡	
Missing	6	0	4	0	2		
Histology [n (%)]							
Serous	284 (79.6)	17 (50)	114 (82)	20 (83.3)	133 (83.1)		
Other Epithelial	73 (20.4)	17 (50)	25 (18)	4 (16.7)	27 (16.9)	<0.001‡	
Missing	0	0	0	0	0		
Cytoreduction [n (%)]							
R0	98 (27.8)	9 (28.1)	41 (29.9)	5 (20.8)	43 (26.9)	0.00+	
Not R0	255 (72.2)	23 (71.9)	96 (70.1)	19 (79.2)	117 (73.1)	0.09‡	
Missing	4	2	2	0	0		
Platinum sensitivity [n (%)]							
Sensitive	156 (55.5)	9 (37.5)	65 (55.1)	11 (68.8)	71 (57.7)		
Resistant	125 (44.5)	15 (62.5)	53 (44.9)	5 (31.3)	52 (42.3)	0.8±	
Missing	76	10	21	8	37		
Treatment Outcome [n (%)]							
Complete Response	169 (57.5)	9 (37.5)	65 (55.1)	9 (52.9)	86 (63.7)		
Not Complete Response	125 (42.5)	15 (62.5)	53 (44.9)	8 (47.1)	49 (36.3)	0.2‡	
Missing	63	10	21	7	25	•	

Table 1. Clinical characteristics of the ovary discovery cohort by MAGEC3 and BRCA2 protein expression level 274

n may vary by characteristic due to missing data

†P-value was calculated using one-way ANOVA test.

‡P-value was calculated using the chi-squared test.

§Chi-squared approximation may be incorrect

3.3. BRCA2 Protein Shows a Weak Negative Correlation with MAGEC3 Expression in Ovarian 276 Cancer Tumor Samples 277

The H-scores from the semi-quantitative analysis of MAGEC3 TMAs in our previous 278 study [36] were correlated with the H-scores of BRCA2 TMAs in this current study using 279 a two-sided Pearson's correlation test. The initial assessment of the relationship between 280 MAGEC3 and BRCA2 expression in the tumor samples revealed no correlation (Figure 281 3A). However, when the cases were stratified based on BRCA2 expression, the MAGEC3 282 H-scores were shown to be inversely correlated with the H-scores of BRCA2 expressors 283 in the ovarian tumor samples (r = -0.15; p<0.05) (Figure 3B), while a positive correlation 284 was observed in the BRCA2 non-expressors (r=0.32; p<0.05) (Figure 3C). 285



Figure 3. Correlation between MAGEC3 protein and BRCA2 C-terminal protein expression in ovarian tumor TMAs (A) No correlation between MAGEC3 and BRCA2 expression in the tumor samples prior to stratification based on BRCA2 expression levels. (B) MAGEC3 H-scores were observed to be inversely correlated with the H-scores of BRCA2 expressors. (C) MAGEC3 H-scores were observed to be positively correlated with the H-scores of BRCA2 non-expressors. 292

3.4. MAGEC3 and BRCA2 Association with Prognosis in Epithelial Ovarian Cancer

286

medRxiv preprint doi: https://doi.org/10.1101/2022.08.17.22278635; this version posted August 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

The impact of age at diagnosis, disease stage, grade, histology, cytoreduction status, 294 and MAGEC3/BRCA2 expression on clinical outcome was analyzed using both univariate 295 and multivariate Cox proportional hazards regression analyses (Table 2). The age at di-296 agnosis, grade, and R0 cytoreduction were univariately associated with prognosis in epi-297 thelial ovarian cancers. Multivariate regression analysis indicated that patients with ad-298 vanced stage disease (HR = 3.28, 95% CI 2.05-5.26, p<0.001) and poorly/undifferentiated 299 tumors (HR = 1.34, 95% CI 1.02-1.76, p=0.04) were statistically significant predictors of 300 survival. 301

Table 2. Discovery cohort survival analysis.

Ovarian Cancer	Univariate Analysis (n=357) †			Multivariate Analysis (n=342)			
Covariate	Risk Level	Hazard Ratio	95% CI	<i>p</i> -value‡	Hazard Ratio	95% CI	<i>p</i> -value‡
Age	+10 years	1.3	(1.18-1.42)	< 0.001	1.32	(1.19-1.46)	< 0.001
Stage	I/II/IIIA/B		Reference			Reference	
	IIIC/IV	3.45	(2.4-4.96)	< 0.001	3.28	(2.05-5.26)	< 0.001
Grade	Well/Moderately differentiated		Reference			Reference	
	Poorly/Undifferentiated	1.15	(0.89-1.49)	0.3	1.34	(1.02-1.76)	0.04
Histology	Other Epithelial		Reference			Stratifier§	
	Serous	1.17	(0.87-1.57)	0.3			
Cytoreduction	R0		Reference			Stratifier§	
	Not R0	2.43	(1.84-3.15)	< 0.001			
MAGEC3 and	Loss~Exp(-)		Reference			Reference	
BRCA2	Normal~Exp(-)	1.29	(0.85-1.95)	0.2	1.14	(0.73-1.79)	0.6
	Loss~Exp(+)	1.17	(0.72-1.89)	0.5	1	(0.61-1.63)	1
	Normal~Exp(+)	1.16	(0.91-1.49)	0.2	1.14	(0.88-1.48)	0.3

tn may vary due to missing data

‡P-value calculated using the Wald test

§Covariate violated the proportional hazards assumption

302 303

Independent evaluation of the relationship between BRCA2 expression and patient 304 outcomes in our cohort of advanced ovarian cancer cases revealed that BRCA2 expression 305 levels did not impact overall survival (log-rank p = 0.198) and progression-free survival 306 (log-rank p = 0.15) in patients with optimal cytoreduction (Figure S2), whereas independ-307 ent evaluation of MAGEC3 expression in our previous study revealed that women with 308 MAGEC3 loss had better progression-free survival (log-rank p=0.002) [36]. In patients 309 with optimal cytoreduction, subgroup analyses of combined expression of MAGEC3 and 310 BRCA2 showed that patients that were BRCA2 expressors with MAGEC3 loss levels had 311 better overall survival compared to patients that were BRCA2 expressors with MAGEC3 312 normal levels (median OS: 127.9 vs 65.3 months; log-rank p=0.035) (Figure 4A). This was 313 also observed for progression free survival (median PFS: 85.3 vs 18.8 months; log-rank 314 p=0.002) (Figure 4B). Conversely, in BRCA2 non-expressor cases, having MAGEC3 loss 315 levels conferred no survival benefit over MAGEC3 normal levels in overall survival (log-316 rank p=0.677) nor progression-free survival (log-rank p=0.753) (Figure 4C+D). 317





Figure 4. Expression of MAGEC3 and BRCA2 predict outcomes in ovarian cancer patients with optimal cytoreduction. Kaplan–Meier plot showing (A) overall survival trends for MAGEC3 normal and loss cases in BRCA2 expressors, (B) progression-free survival trends for MAGEC3 normal 321 and loss cases in BRCA2 expressors, (C) overall survival trends for MAGEC3 normal and loss cases 322 in BRCA2 non-expressors, (D) progression-free survival trends for MAGEC3 normal and loss cases 323 in BRCA2 non-expressors for ovarian cancer patients with optimal cytoreduction. 324

4. Discussion

The aims of this study were to evaluate BRCA2 and MAGEC3 for their influence in 326 epithelial ovarian cancer progression and to assess the clinical significance of their com-327 bined expression. Like BRCA2 [51], evaluation of MAGEC3 protein expression has been 328 identified as a novel prognostic biomarker in ovarian cancer [36]. However, the relation-329 ship between both BRCA2 and MAGEC3 protein expression and their clinical significance 330 in ovarian carcinoma is unknown. 331

The growing importance of IHC as a tool for detecting protein dysfunction via pro-332 tein expression profiles, combined with its ease of use and practicality in identifying the 333 protein of interest within the tumor's cellular compartment, makes it a highly appealing 334 technique to measure validated biomarkers. It proved to be a viable and cost-effective 335 approach for determining BRCA2 protein expression in tumor samples for this study, as 336 similarly reported by other studies [52, 53], as well as for determining MAGEC3 protein 337 expression [36]. We used a dual antibody strategy to discriminate differential expression 338 of BRCA2 at both the N-terminal and C-terminal. Because of its ability to differentiate the 339 wild-type case from mutant and loss cases, C-terminal expression was used to define 340

319 320

325

medRxiv preprint doi: https://doi.org/10.1101/2022.08.17.22278635; this version posted August 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

BRCA2 expression in a large unsequenced cohort. Prior studies also support the idea that341the C-terminal antibody could be useful in screening cancers for BRCA mutations as well342as BRCA2 protein expression in patients with unknown mutation status [45, 52, 54]. Using343this approach, we identified 83.8% (299/357) of patients as BRCA2 expressors and 16.2%344(58/357) as BRCA2 non-expressors.345

In the assessment of the relationship between MAGEC3 and BRCA2 proteins in the 346 tumor samples from the unsequenced cohort, there was no significant correlation of pro-347 tein expression when looking at all cases. However, when we looked at only BRCA2 ex-348 pressors, there was an inverse correlation with MAGEC3 expression. An interesting con-349 jecture emerges that, like other proteins in the MAGE family, MAGEC3 is interacting with 350 an E3 ligase which leads to the ubiquitination and subsequent degradation of a protein, 351 in this case BRCA2. Because this downregulation was only observed in BRCA2 expressors, 352 it is possible that this downregulation will only occur in cells expressing a full-length 353 BRCA2 protein. Preliminary *in vitro* data from our lab supports this hypothesis, as over-354 expression of MAGEC3 results in a reduction of BRCA2 protein level in both fibrosarcoma 355 (HT1080) and ovarian cancer (SKOV3) cell lines [55]. It is important to note that both the 356 HT1080 and SKOV3 were reported to have a wild-type BRCA2 gene [56]. 357

In the unsequenced cohort of patients, survival analyses for overall and progression-358 free survival showed no significant relationship between BRCA2 expression and patient 359 outcomes; whereas our previous study of the same cohort showed that women with 360 MAGEC3 loss had better progression-free survival [36]. For ovarian cancer patients with 361 optimal cytoreduction, combined expression of MAGEC3 and BRCA2 showed that pa-362 tients that were BRCA2 expressors with MAGEC3 loss levels had better overall and pro-363 gression-free survival compared with patients who were BRCA2 expressors with normal 364 MAGEC3 levels. Interestingly, in patients that were BRCA2 non-expressors, MAGEC3 365 loss levels conferred no survival advantage over MAGEC3 normal levels for both overall 366 survival and progression-free survival. Given our results showing that MAGEC3 down-367 regulates BRCA2, we anticipated that higher levels of MAGEC3 would mimic BRCA2 loss 368 status resulting in susceptibility to platinum-based therapies and prolonged survival. 369 However, we note that the correlation observed in these patients was weak and that the 370 in vitro experiments which showed downregulation of BRCA2 were performed at su-371 praphysiological levels of MAGEC3 which would enhance its downregulating effects. A 372 possible explanation for the trends observed is likely related to MAGEC3's additional role 373 in augmenting DNA repair [36]. Additional unpublished data from our lab revealed that 374 ovarian cancer cells expressing MAGEC3 fare better under cisplatin (CDDP) insult by 375 clearing cisplatin adducts [55]. These results led us to conclude that MAGEC3 is a prog-376 nostic marker in cases that are BRCA2 expressors and that its role in DNA repair, as op-377 posed to its weaker role in downregulating BRCA2, is responsible for the trends observed. 378 Because MAGEC3 only retains its prognostic ability in BRCA2 expressors, the combined 379 expression remains a better predictor of outcomes in patients than the individual markers 380 alone. 381

Limitations of our study include the use of only three sequenced ovarian tumor cases 382 with known genomic status to develop our IHC assay, as well as the use of retrospective 383 cohorts for the ovarian cancer TMAs. To reduce batch-processing effects and resulting 384 slide-to-slide variation, the scores were normalized using normal control cores. Slide 385 staining was done by the pathology core facility at Roswell Park Comprehensive Cancer 386 Center using appropriate antibodies for IHC. 387

Despite these limitations, our study has considerable strengths including the analysis 388 of a large cohort of patients to provide insight into the relationship between MAGEC3 and 389 BRCA2 protein expression in ovarian cancer cases. Additionally, the integration and utilization of the automated semi-quantitative IHC profiler built into Image J for assessment 391 of the expression levels of the proteins eliminated any visual bias and high-level observer 392 variation that might have occurred with conventional and manual pathological TMA slide 393 assessment. This was reported as effective in similar studies [57, 58]. 394

5. Conclusions

The combined expression of MAGEC3 and BRCA2 serves as a better predictor of 396 prognosis than either marker alone, as MAGEC3 only retains its prognostic significance 397 in BRCA2 expressors. Ovarian cancer cases expressing BRCA2 with low levels of 398 MAGEC3 fare better than those with normal levels. This is contrary to expectations, given 399 MAGEC3's role in downregulating BRCA2. Given the role of MAGEC3 in augmenting 400DNA repair, we propose that loss of this augmentation explains the favorable trend of 401 patients with low MAGEC3 levels. Further work is needed to confirm this hypothesis. 402

Supplementary Materials: The following supporting information can be downloaded at: 403 www.mdpi.com/xxx/s1, Figure S1: BRCA2 N-terminal expression in the sequenced ovarian tumor 404 cases.; Figure S2: Kaplan-Meier survival curves for independent evaluation of the relationship be-405 tween BRCA2 expression and patient outcomes in the larger cohort of patients with unsequenced 406 advanced ovarian cancer cases. 407

Author Contributions: Conceptualization, K.H.E., E.B.O. and I.A.; methodology, E.B.O., J.E.J., I.A., 408 M.M., S.R.R. and K.H.E.; software, K.H.E.; formal analysis, E.B.O., J.E.J., E.I., S.R.R., E.M.D. and 409 K.H.E.; investigation, E.B.O., J.E.J., I.A., M.M., K.H. and K.H.E.; resources, I.A., M.M. and K.H.E; data 410 curation, E.B.O., J.E.J., I.A. and K.H.E.; writing-original draft preparation, E.B.O. and K.H.E.; writ-411 ing-review and editing, E.B.O., J.E.J., I.A., M.M.D., E.I., E.M.D., S.R.R., K.L.N, J.E.O. and K.H.E.; 412 visualization, E.B.O, J.E.J., I.A., M.M.D., S.R.R., K.H.E., M.M. and K.H.; supervision, S.R.R., K.L.N., 413 J.E.O. and K.H.E.; project administration, E.B.O.; funding acquisition, K.H.E. All authors have read 414 and agreed to the published version of the manuscript. 415

Funding: This research was funded by Department of Defense grants OC170368 and PC180449 (to 416 K.H.E.), the Roswell Park Cancer Center Support Grant P30CA016056, and grants from the Roswell 417 Park Alliance Foundation. 418

Institutional Review Board Statement: The study was conducted in accordance with the Declara-419 tion of Helsinki and approved by the Institutional Review Board of Roswell Park Comprehensive 420 Cancer Center (protocol code BDR109119, 2 December 2019). 421

Informed Consent Statement: Our research was approved as a non-human subject research study; 422 thus, patient consent was waived. The research was classified as non-human subject research be-423 cause it utilized de-identified tissue specimens obtained for other objectives, such as under another 424 study design, as part of an ongoing biorepository, or as residual material following a clinical inter-425 vention. If the specimens were coded, the holder of the re-identification key was prohibited by in-426 stitutional regulations or a direct agreement from providing the key to the investigator or other 427 research employees under any circumstances. Furthermore, the investigator agreed not to seek for 428 Identifiers or re-identification. Roswell Park's biorepositories use an honest broker system to link 429 specimens with associated data and provide it to researchers in a HIPAA-compliant, de-identified 430 format. The study proposal was submitted to the Institutional Assessment Board office for review 431 of human subject protections such as privacy and confidentiality, as well as the safeguarding of 432 identifiable health information, in accordance with Roswell Park policy. 433

Data Availability Statement: The data and code used in this manuscript are available upon request.

Acknowledgments: We would like to acknowledge the Roswell Park Comprehensive Cancer Center pathology core and experimental tumor model resource for their assistance in preparing and reviewing the tissue microarrays for our analysis.

Conflicts of Interest: The authors declare no conflict of interest.

441 442

434

435 436

437

438

439 440

395

Refe	rences	444
1.	Siegel, R.L., et al., <i>Cancer statistics</i> , 2022. CA Cancer J Clin, 2022. 72 (1): p. 7-33.	445
2.	Matulonis, U.A., et al., Ovarian cancer. Nat Rev Dis Primers, 2016. 2: p. 16061.	446
3.	Jayson, G.C., et al., Ovarian cancer. Lancet, 2014. 384(9951): p. 1376-88.	447
4.	Morgan, R.D., et al., PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol, 2018.	448
	81 (4): p. 647-658.	449
5.	Bowtell, D.D., et al., Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer, 2015.	450
	15 (11): p. 668-79.	451
6.	Rendi, M.H., R.L. Garcia, and D.S. Dizon, Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: histopathology.	452
	Available via www. uptodate. com. Last updated February, 2022.	453
7.	Menon, U., et al., Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of	454
	Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, 2021. 397(10290): p. 2182-2193.	455
8.	Guo, T., et al., Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. Cancer Manag Res,	456
	2021. 13 : p. 3081-3100.	457
9.	Badgwell, D. and R.C. Bast, Jr., <i>Early detection of ovarian cancer</i> . Dis Markers, 2007. 23(5-6): p. 397-410.	458
10.	Bast, R.C., Jr., et al., Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev, 2020.	459
	29 (12): p. 2504-2512.	460
11.	Ashworth, A., A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient	461
	<i>in DNA double-strand break repair.</i> J Clin Oncol, 2008. 26 (22): p. 3785-90.	462
12.	Koczkowska, M., et al., Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100	463
	<i>cases.</i> Cancer Med, 2016. 5 (7): p. 1640-6.	464
13.	Girolimetti, G., et al., BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int, 2014. 2014: p.	465
		466
14.	Bolton, K.L., et al., Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 2012. 307 (4): p. 382-90.	467 468
15.	Bai, X., et al., BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1,	469
	improved survival and co-expression of DNA methyltransferases. Oncol Lett, 2014. 7(4): p. 1088-1096.	470
16.	Garg, K., et al., BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J	471
	Surg Pathol, 2013. 37 (1): p. 138-46.	472
17.	Huang, M., et al., <i>Identifying disparities in germline and somatic testing for ovarian cancer</i> . Gynecol Oncol, 2019. 153 (2): p. 297-303.	473 474
18.	Wooster, R., et al., Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 1994. 265(5181): p.	475
	2088-90.	476
19.	Prat, J., A. Ribe, and A. Gallardo, <i>Hereditary ovarian cancer</i> . Hum Pathol, 2005. 36 (8): p. 861-70.	477
20.	Spain, B.H., et al., <i>Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations</i> . Proc Natl Acad Sci U S A, 1999. 96 (24): p. 13920-5.	478 479
21.	Rahman, N. and M.R. Stratton, The genetics of breast cancer susceptibility. Annu Rev Genet, 1998. 32: p. 95-121.	480
22.	Hakansson, S., et al., Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J	481
	Hum Genet, 1997. 60(5): p. 1068-78.	482
23.	Chatterjee, G., et al., Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity. Nucleic	483
	Acids Res, 2016. 44(11): p. 5256-70.	484
24.	Krejci, L., et al., Homologous recombination and its regulation. Nucleic Acids Res, 2012. 40(13): p. 5795-818.	485
25.	Xia, B., et al., Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell, 2006. 22(6): p. 719-729.	486

26.	Baughan, S. and M.A. Tainsky, K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A	487
	Review. Cancers (Basel), 2021. 13(3).	488
27.	Rodriguez-Freixinos, V., et al., <i>Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC)</i> patients. Gynecol Oncol, 2019. 152 (2): p. 270-277.	489 490
28.	Redelico, T., Rucaparib and Niraparib in Advanced Ovarian Cancer. J Adv Pract Oncol, 2019. 10(4): p. 402-408.	491
29.	Banerjee, S. and S. Kaye, PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep, 2011. 13(6): p. 442-	492
	9.	493
30.	Rose, M., et al., PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol, 2020. 8: p.	494
	564601.	495
31.	Moore, K., et al., Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med, 2018. 379(26):	496
	p. 2495-2505.	497
32.	Ganguly, B., et al., Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer, 2016. 8(Suppl 1): p. 15-25.	498
33.	Swisher, E.M., et al., Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol, 2017. 18 (1): p. 75-87.	499 500
34.	Mateo, I., et al., DNA-Revair Defects and Olavarib in Metastatic Prostate Cancer. N Engl J Med. 2015. 373(18): p. 1697-708.	501
35.	Criscuolo, D., et al., Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of	502
	<i>Prostate Cancer Cells to PARP-Inhibitors.</i> Int J Mol Sci, 2019. 20 (12).	503
36.	Ellegate, J., Jr., et al., Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers. Cancers (Basel),	504
	2022. 14(3).	505
37.	Weon, J.L. and P.R. Potts, The MAGE protein family and cancer. Curr Opin Cell Biol, 2015. 37: p. 1-8.	506
38.	Pineda, C.T., et al., Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell, 2015. 160(4): p. 715-728.	507
39.	Gordeeva, O., A. Gordeev, and S. Khaydukov, Expression dynamics of Mage family genes during self-renewal and differentiation	508
	of mouse pluripotent stem and teratocarcinoma cells. Oncotarget, 2019. 10(35): p. 3248-3266.	509
40.	Doyle, J.M., et al., MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell, 2010. 39(6): p. 963-74.	510
41.	Hao, J., et al., Cancer-testis antigen HCA587/MAGE-C2 interacts with BS69 and promotes its degradation in the ubiquitin-proteasome	511
	pathway. Biochem Biophys Res Commun, 2014. 449(4): p. 386-91.	512
42.	Eng, K.H., et al., Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet,	513
	2018. 14 (2): p. e1007194.	514
43.	George, S.H. and P. Shaw, BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol, 2014. 4: p. 5.	515
44.	Tian, Y., et al., 0D/3D coupling of g-C3N4 QDs/hierarchical macro-mesoporous CuO-SiO2 for high-efficiency norfloxacin removal in	516
	photo-Fenton-like processes. J Hazard Mater, 2021. 419 : p. 126359.	517
45.	Liu, Q., et al., A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.	518
	Cancer Biol Ther, 2018. 19 (8): p. 669-675.	519
46.	Wu, Q., et al., MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in	520
	esophageal squamous cell carcinoma. Cancer Commun (Lond), 2021.	521
47.	Daudi, S., et al., <i>Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer</i> . PLoS One, 2014.	522
	9 (8): p. e104099.	523
48.	Uhlen, M., et al., A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics, 2005.	524
10	4 (12): p. 1920-32.	525
49.	Uhlen, M., et al., <i>A proposal for validation of antibodies</i> . Nature methods, 2016. 13 (10): p. 823-827.	526
50.	Varghese, F., et al., IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of	527
-1	immunohistochemistry images of human tissue samples. PLoS One, 2014. 9(5): p. e96801.	528
51.	Huang, J., W. Hu, and A.K. Sood, Prognostic biomarkers in ovarian cancer. Cancer Biomark, 2010. 8(4-5): p. 231-51.	529

52.	Kashima, K., et al., Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies	530
	in familial ovarian cancers. Jpn J Cancer Res, 2000. 91(4): p. 399-409.	531
53.	Vorrius, T.R., et al., Immunohistochemical detection of BRCA-1 and BRCA-2 expression in human breast and ovarian tumors. Journal	532
	of Histotechnology, 2009. 32 (4): p. 202-203.	533
54.	Thorgeirsson, T., et al., Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful	534
	Waiting Cohort. Carcinogenesis, 2016. 37(3): p. 262-268.	535
55.	Aijaz, I. Roswell Park Comprehensive Cancer Center: Buffalo, New York, USA. 2022: Unpublished work.	536
56.	Stordal, B., et al., BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.	537
	Molecular oncology, 2013. 7(3): p. 567-579.	538
57.	Guirado, R., et al., Automated analysis of images for molecular quantification in immunohistochemistry. Heliyon, 2018. 4(6): p.	539
	e00669.	540
58.	Vrekoussis, T., et al., Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ: an RGB-based model.	541
	Anticancer Research, 2009. 29(12): p. 4995-4998.	542
		543